This is a snippet of the transcript, sign up to read more.
Now, moving from the mid-'80s to 2026 or 2027, I'm curious if Chinese robot companies will replicate what Japanese companies did in the '80s, challenging incumbents like Fanuc and ABB. We're starting to see this in humanoid robots. There's still a lot of technology to be worked out with humanoids, which we can discuss further. I recently read that a Chinese company, possibly Pudu, has released a humanoid robot priced at $12,000.
This is a snippet of the transcript, sign up to read more.
I will tell you that the humanoid robots from Agility, Figure, or Aptronic, the major humanoid companies starting up here in the US, are priced probably over $100,000 easily. The Chinese are essentially challenging this by saying, not only do we think we're your peers from a technology perspective, but we're also going to compete aggressively on pricing.
This is a snippet of the transcript, sign up to read more.
I don't know whether the Chinese government is truly funding these losses from these Chinese companies. They might be, but I'm going to speculate. Yes. That's a battle over the next five years or so that you're going to see play out. As an investor, you need to be aware of that cost issue, which is really going to make or break a lot of these American companies. It's not just about innovation; it's also about cost. Large buyers like Procter & Gamble and General Motors are not going to pay a premium for an American robot. They might say they will for publicity, but if one is priced at $120,000 and the other at $35,000, they're going to buy the $35,000 cheaper Chinese robot, guaranteed.
This is a snippet of the transcript, sign up to read more.
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2025 IP 1 Ltd. All rights reserved.